[S-1/krestin immunochemotherapy for patients with advanced gastric cancer].
BACKGROUND
S-1 mono-therapy for advanced gastric cancer is hard to continue in some patients due to adverse events. We retrospectively examined the patients who received S-1/Krestin( PSK) immunochemotherapy for advanced gastric cancer.


METHODS
During September 2006 to August 2008, 3 patients had received S-1/PSK. S-1 was given for 6-week schedule or 3-week schedule, and PSK was for everyday during the S-1 treatment.


RESULTS
Cases 1 and 2 had lymph node metastases after surgery. Case 3 had peritoneal metastasis. The median treatment duration was 112 days. The median overall survival was 552 days. All patients stopped the treatment due to progression of disease. There were no patients who stopped the treatment due to adverse events.


CONCLUSIONS
PSK may increase the compliance of S-1.
Dept. of Gastrointestinal Surgery, Kanagawa Cancer Center.
Toru
T
Aoyama
Takaki
T
Yoshikawa
Tsutomu
T
Hayashi
Hiroshi
H
Kuwabara
Yo
Y
Mikayama
Takashi
T
Ogata
Haruhiko
H
Cho
Akira
A
Tsuburaya
Yasushi
Y
Rino
Munetaka
M
Masuda
D000328:Adult; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D011509:Proteoglycans / Q000008:administration & dosage / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D005641:Tegafur / Q000008:administration & dosage / Q000627:therapeutic use*
D004338:Drug Combinations; D011509:Proteoglycans; C079198:S 1 (combination); D005641:Tegafur; C010770:polysaccharide-K; D010094:Oxonic Acid